Michela Casanova

18PUBLICATIONS
150CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSpeech recognitionMolecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Oct 16, 2025
Childhood, Adolescent and Young Adult Poor-Prognosis Rhabdomyosarcoma.

Ajla T Wasti, Gianni Bisogno, Raquel Hladun

|Mar 07, 2025
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial.

Gianni Bisogno, Julia Chisholm, Raquel Hladun

|Oct 16, 2024
Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998.

Julia Chisholm, Henry Mandeville, Madeleine Adams

|Sep 27, 2024
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype.

Maura Massimino, Francesco Barretta, Chiara Dossena

|Aug 12, 2024
Being diagnosed with a rhabdomyosarcoma in the era of artificial intelligence: Whom can we trust?

Carlo Alfredo Clerici, Alice Bernasconi, Paolo Lasalvia

Pageof 3

Frequent Collaborators

10 joint publications

Andrea Ferrari

8 joint publications

Gianni Bisogno

7 joint publications

Julia Chisholm

7 joint publications

Johannes H M Merks